Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Home Is Where The Bard Is

Patient, if not long-suffering, shareholders in Rochester Medical (NASDAQ:ROCM) finally got their vindication on Wednesday, as Bard (NYSE:BCR) stepped up with an all-cash offer for this largely home-care focused urology devices company. Although this deal is not going to radically change the growth outlook for Bard, it is a logical buy-vs-build move that should add long-term value and give the company entry into a market that should be poised for growth in the coming years.

Farewell, And Thanks For The Profits

Rochester Medical announced that it had received and accepted a $262 million all-cash deal from Bard worth $20 per share. That gives Rochester Medical shareholders a 45% premium to Tuesday's close, and the stock hasn't...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details